Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Naoki Kohira"'
Autor:
Nami Yasuda, Tomoko Fujita, Takahiro Fujioka, Mei Tagawa, Naoki Kohira, Kensho Torimaru, Sumiko Shiota, Takanori Kumagai, Daichi Morita, Wakano Ogawa, Tomofusa Tsuchiya, Teruo Kuroda
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Multidrug-resistant Pseudomonas aeruginosa (MDRP) is one of the most important pathogens in clinical practice. To clarify the mechanisms contributing to its emergence, we isolated MDRPs using the P. aeruginosa PAO1, the whole genome sequence
Externí odkaz:
https://doaj.org/article/8c6cc076f38940e080b687e7b1942031
Autor:
Naoki Kohira, Meredith A. Hackel, Yoshino Ishioka, Miho Kuroiwa, Daniel F. Sahm, Takafumi Sato, Hideki Maki, Yoshinori Yamano
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 22, Iss , Pp 738-741 (2020)
Objective: To investigate possible mechanistic factors to explain cefiderocol (CFDC) non-susceptibility, we characterized 38 clinical isolates with a CFDC minimum inhibitory concentration (MIC) of >4 μg/mL from a multi-national surveillance study. M
Externí odkaz:
https://doaj.org/article/72046124350d4e22babc3f2d708785a5
Autor:
Shintaro Mikuni, Kota Kodama, Akira Sasaki, Naoki Kohira, Hideki Maki, Masaharu Munetomo, Katsumi Maenaka, Masataka Kinjo
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0130933 (2015)
FtsZ is an attractive target for antibiotic research because it is an essential bacterial cell division protein that polymerizes in a GTP-dependent manner. To find the seed chemical structure, we established a high-throughput, quantitative screening
Externí odkaz:
https://doaj.org/article/c14e36e48df9484e8fde4996d1efbdce
Autor:
Naoki Kohira, Meredith A Hackel, Merime Oota, Miki Takemura, Fupin Hu, Hiromichi Mizuno, Daniel F Sahm, Yoshinori Yamano
Publikováno v:
Journal of Global Antimicrobial Resistance. 32:181-186
Cefiderocol (CFDC) is a parenteral siderophore cephalosporin that is active against Gram-negative bacteria, including carbapenem-resistant isolates. We report the in vitro activity of CFDC and other antibiotics against 1,738 clinical isolates of Gram
Autor:
Hiroyuki Shimaoka, Naoki Kohira, Hidenori Yoshizawa, Yuki Murakami, Hitoshi Murai, Masayuki Sano
Publikováno v:
Chemistry Letters. 49:1497-1500
Third-generation cephalosporins possess broad spectrum and potent activities against Gram-positive and Gram-negative bacteria. In order to establish a general methodology for improving the oral bio...
Autor:
Motohiro Fujiu, Tomoyuki Kawachi, Jun Sato, Kazuo Komano, Satoshi Miyagawa, Katsuki Yokoo, Satoru Shibuya, Kenji Yamawaki, Soichiro Sato, Hiroki Kusano, Naoki Kohira, Toshiaki Aoki
Publikováno v:
ACS Infectious Diseases. 6:3034-3047
By the emergence and worldwide spread of multi-drug-resistant Gram-negative bacteria, there have been growing demands for efficacious drugs to cure these resistant infections. The key mechanism for resistance to β-lactam antibiotics is the productio
Autor:
Naoki Kohira, Hiroyuki Shimaoka, Hidenori Yoshizawa, Masayuki Sano, Hitoshi Murai, Yuki Murakami
Publikováno v:
Chemistry Letters. 49:1501-1503
Macrocyclization can help improve pharmacological activity, metabolic stability, cell permeability and oral absorption to create better drug candidates. For example, enhancing the oral absorption o...
Autor:
Hideki Maki, Kenji Yamawaki, Toshiaki Aoki, Daiki Nagamatsu, Ryosuke Watari, Motohiro Fujiu, Hiroki Kusano, Yuya Hirakawa, Kazuo Komano, Sachi Kanazawa, Emi Kashiwagi, Naoki Kohira, Satoru Shibuya, Soichiro Sato, Tomoyuki Kawachi, Jun Sato, Katsuki Yokoo
Publikováno v:
Journal of medicinal chemistry. 64(13)
Coadministration of β-lactam and β-lactamase inhibitor (BLI) is one of the well-established therapeutic measures for bacterial infections caused by β-lactam-resistant Gram-negative bacteria, whereas we have only two options for orally active BLI,
Autor:
Hideki Maki, Takafumi Sato, Miho Kuroiwa, Naoki Kohira, Meredith Hackel, Daniel F. Sahm, Yoshino Ishioka, Yoshinori Yamano
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 22, Iss, Pp 738-741 (2020)
Objective To investigate possible mechanistic factors to explain cefiderocol (CFDC) non-susceptibility, we characterized 38 clinical isolates with a CFDC minimum inhibitory concentration (MIC) of >4 μg/mL from a multi-national surveillance study. Me
Autor:
Masakatsu Tsuji, Tsukasa Ito-Horiyama, Yoshinori Yamano, Akinobu Ito, Naoki Kohira, Takafumi Sato, Rio Nakamura, Stephen Rittenhouse, Joshua West
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:729-734
S-649266 is a novel siderophore cephalosporin antibiotic with a catechol moiety on the 3-position side chain. Two sets of clinical isolate collections were used to evaluate the antimicrobial activity of S-649266 against Enterobacteriaceae . These set